Evotec SE (EVO) Restructuring Costs (2009 - 2025)
Evotec SE (EVO) reported Restructuring Costs of -$1629.7 for Q4 2025, down 121.48% on a YoY basis from $7587.0 in Q4 2024, and down 1390.74% sequentially from $126.26 in Q3 2025.
Evotec SE (EVO) Restructuring Costs (2009 - 2025) Analysis & Trends
Evotec SE (EVO) has 3 years of Restructuring Costs data on file, last reported at -$1629.7 in Q4 2025.
- For the quarter ending Q4 2025, Restructuring Costs fell 121.48% year-over-year to -$1629.7; the trailing twelve-month figure through Dec 2025 stood at $12891.5 (down 99.68% YoY), and the FY2025 full-year result was -$698.43, up 98.81% from the prior year.
- Restructuring Costs fell to -$1629.7 in Q4 2025, from $126.26 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $7587.0 in Q4 2024 to a low of -$1629.7 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,629.66 |
| Sep 30, 2025 | 126.26 |
| Dec 31, 2024 | 7,587.03 |
| Sep 30, 2024 | 6,807.86 |
| Dec 31, 2009 | 3.98 Mn |
| Jun 30, 2009 | 3,665.56 |
| Mar 31, 2009 | 1.89 |